EDF Health

The Next Mile Marker on the Road to High Throughput In Vitro Screening?

By John Balbus / Published: June 24, 2008

John Balbus, M.D., M.P.H., is Chief Health Scientist.

A new paper by Shaw et al., published in May in the Proceedings of the National Academy of Sciences, “suggests a generalizable and scalable method for the systematic characterization and comparison of novel nanomaterials” using high throughput in vitro tests.  Does this mean that the National Academy of Sciences’ vision for toxicity testing in the 21st century – proposed for conventional chemicals – is already here for nanomaterials?  Not quite.  Read More »

Also posted in Health science, Nanotechnology / Tagged , , , | Comments are closed

In Vitro Risk Assessment for a Nano Fuel Additive: Tanks or No Tanks?

By John Balbus / Published: May 9, 2008

John Balbus, M.D., M.P.H., is Chief Health Scientist.

The history of health and environmental impacts of fuel additives is not a pretty one.  From tetra-ethyl lead to methyl tert-butyl ether (MTBE), we’ve learned the hard way that what goes in the tank ends up in our bodies and the environment sooner or later.  Getting a thorough understanding of the potential risks of a new fuel additive at an early stage is essential to avoid a lot of harm, suffering, and economic costs down the line.

A new study by Park et al. has assessed the potential respiratory risks of a fuel additive called Envirox (nanoparticulate cerium oxide), giving it a clean bill of health based only on in vitro tests.  Is this the vision of the future of risk assessment?  Should we feel safe? Read More »

Also posted in Health science, Nanotechnology / Tagged , , | Comments are closed

On the Road to In Vitro Testing: Are We There Yet?

By John Balbus / Published: March 18, 2008

John Balbus, M.D., M.P.H., is Chief Health Scientist.

EPA’s recently released draft Nanotechnology Research Strategy (NRS) proposes a tiered testing system to evaluate human toxicity of nanomaterials.  It puts in vitro tests, or those done in test tubes and petri dishes as opposed to living animals, front and center.  EPA says the results of the first, in vitro tier will be used for guidance on “what health endpoints to monitor” and the second, in vivo tier will then help “identify those in vitro assays that correlate with in vivo nanomaterial toxicity or health effects.”

Wait a second.  If the in vivo testing is necessary in order to figure out what the in vitro testing results really mean, how can the agency use the in vitro testing results to figure out what health endpoints to monitor?  This cart and horse confusion is a serious matter. Read More »

Also posted in Health science, Nanotechnology / Tagged , , | Read 1 Response